Safety and tolerability of MEDI-551 in patients with relapsing forms of multiple sclerosis: results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study

被引：0
|
作者：
Agius, M. [1 ]
Klodowska-Duda, G. [2 ]
Maciejowski, M. [3 ]
Potemkowski, A. [4 ]
Sweeny, S. [5 ]
Li, J. [6 ]
Yao, W. [5 ]
Patra, K. [5 ]
Ratchford, J. N. [5 ]
Katz, E. [5 ]
Flor, A. [5 ]
机构：
[1] Univ Calif Davis, Dept Neurol, Sacramento, CA 95817 USA
[2] Neurocare, Katowice, Poland
[3] KMK Clin Sp Zoo, NZOZ RAWA MED, Katowice, Poland
[4] Osrodek Badan Klin Znych Indywidualnej Specjalist, Szczecin, Poland
[5] Medimmune Inc, Gaithersburg, MD 20878 USA
[6] MedImmune, Mountain View, CA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P528
引用
收藏
页码：235 / 236
页数：2
相关论文
共 50 条
  • [1] Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study
    Agius, Mark A.
    Klodowska-Duda, Gabriela
    Maciejowski, Maciej
    Potemkowski, Andrzej
    Li, Jing
    Patra, Kaushik
    Wesley, Jacob
    Madani, Soraya
    Barron, Gerard
    Katz, Eliezer
    Flor, Armando
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (02) : 235 - 245
  • [2] SAFETY AND TOLERABILITY OF MEDI-551 IN SUBJECTS WITH SYSTEMIC SCLEROSIS (SSC): RESULTS FROM A PHASE 1 RANDOMIZED, PLACEBO-CONTROLLED ESCALATING SINGLE-DOSE STUDY
    Schiopu, E.
    Chatterjee, S.
    Hsu, V.
    Flor, A.
    Pavlovic, D.
    Patra, K.
    Li, J.
    McKeever, K.
    Herbst, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 562 - 562
  • [3] Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study
    Elena Schiopu
    Soumya Chatterjee
    Vivien Hsu
    Armando Flor
    Daniel Cimbora
    Kaushik Patra
    Wenliang Yao
    Jing Li
    Katie Streicher
    Kathleen McKeever
    Barbara White
    Eliezer Katz
    Jorn Drappa
    Sarah Sweeny
    Ronald Herbst
    Arthritis Research & Therapy, 18
  • [4] Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study
    Schiopu, Elena
    Chatterjee, Soumya
    Hsu, Vivien
    Flor, Armando
    Cimbora, Daniel
    Patra, Kaushik
    Yao, Wenliang
    Li, Jing
    Streicher, Katie
    McKeever, Kathleen
    White, Barbara
    Katz, Eliezer
    Drappa, Jorn
    Sweeny, Sarah
    Herbst, Ronald
    ARTHRITIS RESEARCH & THERAPY, 2016, 18
  • [5] Preliminary CHOICE results: a phase 2, randomised, doubleblind, placebo-controlled multicentre study of subcutaneous daclizumab in patients with active, relapsing forms of multiple sclerosis on interferon beta
    Montalban, X.
    Wynn, D.
    Kaufman, M.
    Wang, M.
    Fong, A.
    MULTIPLE SCLEROSIS, 2007, 13 : S18 - S18
  • [6] Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study
    Rohit Aggarwal
    Joachim Schessl
    Christina Charles-Schoeman
    Zsuzsanna Bata-Csörgő
    Mazen M. Dimachkie
    Zoltan Griger
    Sergey Moiseev
    Chester V. Oddis
    Elena Schiopu
    Jiri Vencovský
    Irene Beckmann
    Elisabeth Clodi
    Todd Levine
    Arthritis Research & Therapy, 26
  • [7] Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study
    Aggarwal, Rohit
    Schessl, Joachim
    Charles-Schoeman, Christina
    Bata-Csorgo, Zsuzsanna
    Dimachkie, Mazen M.
    Griger, Zoltan
    Moiseev, Sergey
    Oddis, Chester V.
    Schiopu, Elena
    Vencovsky, Jiri
    Beckmann, Irene
    Clodi, Elisabeth
    Levine, Todd
    ARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)
  • [8] A placebo-controlled, safety, tolerability, dose escalation, PK study of various doses of intravenous Antegren in patients with multiple sclerosis (MS)
    Sheremata, WA
    Vollmer, TL
    Stone, LA
    Willmer-Hulme, AJ
    Koller, ME
    NEUROLOGY, 1998, 50 (04) : A63 - A64
  • [9] Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
    Cadavid, Diego
    Mellion, Michelle
    Hupperts, Raymond
    Edwards, Keith R.
    Calabresi, Peter A.
    Drulovic, Plena
    Giovannoni, Gavin
    Hartung, Hans-Peter
    Arnold, Douglas L.
    Fisher, Elizabeth
    Rudick, Richard
    Mi, Sha
    Choi, Yi
    Li, Jie
    Zhang, Yiwei
    Cheng, Wenting
    Xu, Lei
    Zhu, Bing
    Green, Susan M.
    Chang, Ih
    Deykin, Aaron
    Sheikh, Sarah, I
    LANCET NEUROLOGY, 2019, 18 (09): : 845 - 856
  • [10] Teriflunomide Efficacy and Safety in Patients with Relapsing Multiple Sclerosis: Results from TOWER, a Second, Pivotal, Phase 3 Placebo-Controlled Study
    Miller, Aaron
    Kappos, Ludwig
    Comi, Giancarlo
    Confavreux, Christian
    Freedman, Mark
    Olsson, Tomas
    Wolinsky, Jerry
    Bagulho, Teresa
    Delhay, Jean-Luc
    Zheng, Yan
    Truffinet, Philippe
    O'Connor, Paul
    NEUROLOGY, 2013, 80
12345